First-line treatment with surufatinib and toripalimab provided disease control in 100% of patients with advanced, PD-L1+ NSCLC.
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
The investigational drug VT3989 appears safe and can produce responses in patients with refractory mesothelioma or sarcoma, a phase 1 study suggests.
Combination dabrafenib and trametinib has demonstrated activity against multiple rare cancers harboring the BRAF V600E mutation.
Adjuvant chemotherapy provides a survival benefit for patients with hormone receptor-positive mucinous breast cancer, a retrospective study suggests.
After the BCG shortage began, patients with non-muscle invasive bladder cancer were less likely to receive a full course of induction with any drug.
Antibiotics may prevent bacteria-mediated chemoresistance in patients with metastatic pancreatic cancer, a new study suggests.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Adding ramucirumab to first-line chemotherapy does not improve outcomes in patients with advanced pancreatic ductal adenocarcinoma, a study suggests.
